News Category
Enodia Therapeutics has named Henrik Torp Nielsen as Chief Financial Officer, bringing nearly two decades of biopharma finance experience to guide the...
Certified-PEP has published a 100-point comparison of 10 research peptide suppliers, drawing attention to inconsistencies in Certificates of Analysis,...
Creative Biolabs is spotlighting three-dimensional tumor organoid and immune cell co-culture services that let preclinical researchers study CAR-T act...
Creative Biolabs' new dual-vesicle platform combines OMV and exosome engineering to help researchers overcome CAR-T infiltration, persistence, and saf...
GeoVax's $1 million revolving loan from Bowery Consulting Group comes with significant governance changes, as the lender nominates three new directors...
TransCode Therapeutics' TTX-MC138 met its primary safety endpoint in a Phase 1a trial, with no dose-limiting toxicities and early signs of disease sta...
Oncotelic Therapeutics has published a peer-reviewed study showing its PDAOAI platform identified a four-gene prognostic signature in hepatocellular c...
Tonix Pharmaceuticals will report third-quarter 2026 financial results on Nov. 9, 2026, providing investors with a key update on its commercial launch...
A UK study reveals that clearing immune fog can intercept lung cancer before diagnosis, potentially revolutionizing early treatment and saving lives.
Scinai Immunotherapeutics' CDMO subsidiary signed a $5.1 million development and clinical manufacturing agreement with a Nasdaq-listed biopharmaceutic...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its lead multiple sclerosis drug candidate, Lucid-MS, into a Phase...
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies to cut animal testing by up to 95% while accelerating preclinical...
Lantern Pharma's regulatory and IRB approvals in Taiwan for Part 2 of its Phase 2 HARMONIC trial of LP-300 represent a key step in advancing a biomark...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to initiate a Phase 2 trial of Luci...
VERAXA Biotech's FDA-aligned New Approach Methodologies could significantly reduce animal testing and accelerate preclinical development of its antibo...
XORTX Therapeutics is advancing XORLO, a proprietary oxypurinol formulation, toward an FDA new drug application as gout cases are expected to rise sig...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher Scientific marks a crucial step toward launching a Phase 2 trial of Lucid-MS, a potent...
Telomir Pharmaceuticals' $5.6 million PIPE financing will fund the clinical development of Telomir-Zn, a potential first-in-class therapy for triple-n...
NanoViricides will present at the NIBA 153rd Investment Conference on October 7, 2026, highlighting its broad-spectrum antiviral NV-387, which is in P...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher for its Lucid-MS Phase 2 trial marks a critical step toward developing a first-in-clas...
New research reveals that the skull may harbor a local immune system for the brain, potentially opening doors to novel treatments for brain diseases a...
Kairos Pharma's ENV-105 combined with apalutamide demonstrated a statistically significant improvement in progression-free survival for metastatic cas...
AXIM Biotechnologies has submitted a 510(k) to the FDA for a rapid, point-of-care tear lactoferrin test that could simplify and expand objective dry e...
GeoVax will present its next-generation MVA-X vaccine and continuous cell-line manufacturing platform at a major vaccine conference, potentially trans...
A new intraoperative test developed by the University of Nottingham and deployed by NHS England can identify a brain tumor's genetic makeup in about t...
NanoViricides has provided an update on its Phase II clinical trial of NV-387 Oral Gummies for Ebola, highlighting the potential of an oral antiviral ...
A new blood-based method for identifying cancer-specific proteins could eliminate the need for surgical tumor biopsies, potentially accelerating the d...
Helix BioPharma has appointed four new directors and named Karen Krumeich as Chair, strengthening its governance and expertise as it advances its onco...
Viromed Medical AG reported progress in product development and market launch for its cold plasma technologies in H1 2026, while confirming its full-y...
A new protein discovery by South Korean researchers could lead to more effective treatments for glioblastoma, the deadliest form of brain cancer, whil...
In vitro ADME studies are critical for early assessment of drug candidates, helping to avoid late-stage clinical trial failures and streamline develop...
GeoVax's next-generation MVA-X vaccine provides durable single-dose protection against highly pathogenic Clade I mpox virus in preclinical models, pot...
Onco-Innovations is aligning manufacturing, preclinical, and regulatory activities for its lead cancer candidate ONC010, aiming to disrupt DNA repair ...
VERAXA Biotech's appointment of Raju Willener as CFO brings decades of capital markets expertise as the company advances its BiTAC oncology platform, ...
Apimeds Pharmaceuticals US has hired IBN to enhance corporate communications, aiming to raise investor awareness of its diversified blockchain and bio...
Regentis Biomaterials is advancing its regenerative medicine platform with GelrinC, a treatment for knee cartilage injuries, targeting a large U.S. ma...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property position in developing a novel intranasal treatment for PTSD, add...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant that supports cartilage regeneration, as a potential new treatment for k...
Med-X is expanding its Nature-Cide natural pest control brand as it prepares for a Nasdaq debut, potentially disrupting the conventional pesticide mar...
Telomir Pharmaceuticals' Telomir-Zn demonstrated growth inhibition in human and canine osteosarcoma models, potentially opening a new translational pa...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS allows the company to initiate a Phase 2 trial in multiple sclerosis, potentially offering a...
GeoVax has entered an agreement with CEPI to use its Centralised Laboratory Network for independent testing of GEO-MVA, which could help diversify glo...
Tevard Biosciences and collaborators published preclinical research demonstrating that engineered suppressor tRNAs can restore full-length dystrophin ...
Creative Biolabs has expanded its functionalized lipid-based delivery system development to help researchers address stability, targeting, and control...
Creative Biolabs has broadened its single-cell and single-nucleus RNA sequencing and multi-omics services to help researchers overcome sample processi...
A comprehensive review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct functional subsets, offering new ta...
GeoVax Labs is appealing a Nasdaq delisting determination while maintaining its strategic focus on advancing its mpox vaccine and cancer immunotherapy...
Regentis Biomaterials reported positive progress in its Phase III GelrinC trial and received European approval for a manufacturing process that boosts...
